RT Journal Article SR Electronic T1 â–¼Pioglitazone and â–¼rosiglitazone for diabetes JF Drug and Therapeutics Bulletin JO Drug Ther Bull FD BMJ Publishing Group Ltd SP 65 OP 68 DO 10.1136/dtb.2001.39965 VO 39 IS 9 YR 2001 UL http://dtb.bmj.com/content/39/9/65.abstract AB Relevant BNF section: 6.1.2.3&#9660Pioglitazone* (Actos - Takeda) and &#9660rosiglitazone* (Avandia - GlaxoSmithKline) belong to a new class of oral antidiabetic medicines (the glitazones or thiazolidinediones). Both are licensed in the UK for "oral combination treatment of type 2 diabetes mellitus in [narrowly defined groups of] patients with insufficient glycaemic control despite maximal tolerated dose of oral monotherapy with either metformin or a sulphonylurea". They are not licensed for use as monotherapy, in combination with insulin, or as part of triple therapy with metformin or a sulphonylurea. What can pioglitazone and rosiglitazone offer in the management of patients with type 2 diabetes?